ResMed (RMD) : The money flow analysis of ResMed (RMD) indicates a $21.53 million of outflow was on downticks, whereas, the investors on Tuesday gobbled up stocks worth $32.37 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.5 and so was the total money flow at $10.84 million. A solid up-down ratio of 1.75 in block trades indicates that the investors are accumulating the stock on weakness. The bulls lapped up $25.23 million worth of block trades on upticks. Only $14.38 million worth of the stock exchanged hands on downticks. The money flow was $10.85 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of ResMed (RMD), pushing it down by -1% for the day. The stock slid $0.68 and traded at $67.22 during the day. Nonetheless, the stock is -2.62% over the previous weeks close.
Also, Jefferies downgrades its rating on ResMed (NYSE:RMD). The global brokerage major lowers the current price target from $60 per share to $58 per share. Analysts at the Jefferies have a current rating of Underperform on the shares. The shares were previously rated Hold. The rating by the firm was issued on August 23, 2016.
ResMed Inc. has lost 0.15% in the last five trading days and dropped 3.31% in the last 4 weeks. ResMed Inc. is up 14.14% in the last 3-month period. Year-to-Date the stock performance stands at 27.11%.
ResMed (NYSE:RMD): The stock opened at $67.74 on Tuesday but the bulls could not build on the opening and the stock topped out at $68.11 for the day. The stock traded down to $67.02 during the day, due to lack of any buying support eventually closed down at $67.22 with a loss of -1.00% for the day. The stock had closed at $67.90 on the previous day. The total traded volume was 1,392,920 shares.
In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Resmed Inc, Taylor Ronald R had purchased shares worth of $171,926 in a transaction dated on August 17, 2016. A total of 2,487 shares were purchased at a price of $69.13 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
ResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.